Protirelin (Thyrotropin TRH) and Brain Cell Signaling

Protirelin is a synthetic tripeptide (L-pyroglutamyl-L-h histidyl-L-proline amide) that has been developed as an analogue of a small peptide endogenously produced in hypothalamic cells called thyrotropin-releasing hormone (TRH).⁽¹⁾ It is thought that Protirelin may mimic the functions of TRH, potentially engaging in similar interactions with TRH receptors, namely TRH-1 and TRH-2, on anterior pituitary gland cells. It has been proposed that when Protirelin binds to these receptors, which are G protein-coupled, a cascade of intracellular events may be initiated. This cascade may contribute to the release of thyroid-stimulating hormone (TSH).

Once released, TSH is believed to act on the thyroid gland cells to stimulate the synthesis and secretion of thyroid hormones, such as triiodothyronine (T3) and thyroxine (T4). In addition to its potential role in regulating thyroid hormone production, Protirelin has been investigated for potential influence on other hormones like prolactin and a range of physiological processes, including autonomic regulation, neuronal excitability (possibly through interactions with ion channels like TREK-1), cellular aging and responses to oxidative stress.

 

Research

Protirelin (Thyrotropin TRH) and hypothalamic hormones

As a TRH analog, Protirelin’s main potential action is to mimic the function of the native hormone. Therefore, researchers such as Fliers et al. suggest that Protirelin may serve as a helpful tool for investigating the cellular pathways that govern TRH synthesis.⁽²⁾ When applied in controlled studies using murine models, this synthetic peptide might be of interest in explorations of the intracellular signaling events in TRH-producing cells. It is posited that protirelin might mimic aspects of endogenous TRH activity, thereby allowing researchers to monitor downstream impacts on gene expression and transcription factor activation. For instance, protirelin may help reveal how thyroid hormone feedback, possibly mediated by T₃, intersects with the cellular mechanisms that regulate TRH mRNA levels. Moreover, since cytokines such as interleukin-1 have been suggested to modulate TRH expression, protirelin might be employed to explore whether these immune mediators converge on shared intracellular pathways within TRH neurons.

Protirelin (Thyrotropin TRH) and Brain Signaling

Protirelin has also been posited to modulate CNS function independently of its role in pituitary or thyroid stimulation. Marangell et al. suggest that high-affinity receptors for protirelin are distributed throughout the brain, with particularly high density in regions such as the amygdala and hippocampus.⁽³⁾ This distribution suggests a possible role in modulating CNS activity, including impacts on arousal, motor activity, and neurotransmitter systems such as serotonin and dopamine. Protirelin has been observed to influence both hyperactive and hypoactive (depressive) states in murine models, potentially indicating a state-dependent mechanism of action.

For instance, the researchers shared that upon experimentation, more than half of the research models responded to Protirelin, “defined as a 50% or greater reduction in an abbreviated Hamilton Rating Scale for Depression score”. Furthermore, Bunevicius et al. suggest that hypothalamic cell exposure to the peptide may induce arousal from hibernation in certain research models, further supporting its potential CNS-modulating impacts.⁽⁴⁾ In murine models, protirelin has been suggested to modulate activity levels in a state-dependent manner, increasing activity in hypoactive states and decreasing it in hyperactive states. This bidirectional modulation suggests a potential role in balancing CNS activity, possibly through interactions with neurotransmitter systems. Despite these findings, the precise mechanisms by which protirelin exerts its CNS impacts remain unclear. Its interactions with neurotransmitter systems, such as serotonin and dopamine, suggest a potential role in modulating behavioral patterns, which may reduce the extent and nature of these interactions and require further exploration.

One potential mechanism highlighted by Nie et al. may be related to Protirelin, which may reduce the release of excitatory amino acids in hippocampal brain cells. When stimulated by high potassium levels—an approach often called upon by researchers to provoke the release of excitatory neurotransmitters—the cells that had been exposed to Protirelin apparently exhibited a marked reduction in peak glutamate and aspartate release compared to control cells. This inhibitory potential was apparently robust across all evaluated concentrations of the peptide and persisted for some time following the end of stimulation. Yet Protirelin did not seem to alter basal levels of glutamate or aspartate when no depolarizing stimulus was applied, suggesting a more selective action that becomes noticeable mainly under excitatory challenge.

As noted, Protirelin may also modulate a variety of neurotransmitter systems—such as those involving serotonin, dopamine, acetylcholine, and norepinephrine—which may contribute to its overall neuromodulatory action. Researchers like Callahan et al. suggest that these interactions, along with the engagement of neural circuits, perhaps involving vagal afferents and brainstem nuclei, may underlie the observed potential of the peptide. The researchers also suggest that repeated evaluation and experimentation with Protirelin on the same cell cultures may induce tolerance.

A study by Diz et al. also suggests that Protirelin may influence sympathetic and parasympathetic signaling in a region-specific manner within the preoptic and hypothalamic nuclei. The peptide has been suggested to increase blood pressure (7%) and heart rate (19%), with heart rate responses being more pronounced in experimental models. This is posited to involve partial inhibition of parasympathetic nerves that regulate the cardiovascular system. Additionally, adrenal catecholamine release also mediates some of the actions of Protirelin. This suggests that “both inhibition of the parasympathetic and activation of the sympathetic nervous systems may contribute to the response observed,” though adrenal involvement has not been confirmed so far.

Protirelin (Thyrotropin TRH) and Synaptic Plasticity

Research by Watanave et al. suggests that Protirelin may have the potential to modulate synaptic plasticity in experimental settings in TRH‐deficient murine models. Lack of TRH appears to impede normal signaling of inhibiting neuro mediators. Protirelin was suggested to restore normal signaling in these models, and this rescue was apparently dependent on the nitric oxide (NO)–cGMP pathway; when NO synthesis was inhibited, Protirelin restorative potential was lost, whereas direct exposure of a membrane‐permeable cGMP analog was observed to reinstate normal signaling.

Research by Mellow et al. also posits that Protirelin may affect cholinergic transmission, based on murine models which report an observed modestly better support in semantic memory; this suggests that protirelin may selectively affect cognitive processes, although its impact on other cognitive domains such as attention, episodic, and visual memory was minimal. It remains uncertain whether the changes in semantic memory have a direct impact on cognitive circuits or are secondary to the overall arousal support that the peptide may also produce in research settings.

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

 

References:

1. Boler J, Enzmann F, Folkers K, Bowers CY, Schally AV. The identity of chemical and hormonal properties of the thyrotropin-releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun. 1969 Nov 6;37(4):705-10. doi: 10.1016/0006-291x(69)90868-7. PMID: 4982117.
2. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab. 1997 Dec;82(12):4032-6. doi: 10.1210/jcem.82.12.4404. PMID: 9398708.
3. Marangell LB, George MS, Callahan AM, Ketter TA, Pazzaglia PJ, L’Herrou TA, Leverich GS, Post RM. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry. 1997 Mar;54(3):214-22. doi: 10.1001/archpsyc.1997.01830150034007. PMID: 9075462.
4. Bunevicius R, Matulevicius V. Short-lasting behavioral effects of thyrotropin-releasing hormone in depressed women: results of a placebo-controlled study. Psychoneuroendocrinology. 1993;18(5-6):445-9. doi: 10.1016/0306-4530(93)90019-h. PMID: 8416053.
5. Nie Y, Schoepp DD, Klaunig JE, Yard M, Lahiri DK, Kubek MJ. Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. Brain Res. 2005 Aug 23;1054(1):45-54. doi: 10.1016/j.brainres.2005.06.077. PMID: 16055093.
6. Callahan AM, Frye MA, Marangell LB, George MS, Ketter TA, L’Herrou T, Post RM. Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics. Biol Psychiatry. 1997 Feb 1;41(3):264-72. doi: 10.1016/s0006-3223(97)00372-7. PMID: 9024949.
7. Diz DI, Jacobowitz DM. Cardiovascular effects are produced by injections of thyrotropin-releasing hormones into specific preoptic and hypothalamic nuclei in rats. Peptides. 1984 Jul-Aug;5(4):801-8. doi: 10.1016/0196-9781(84)90025-1. PMID: 6436799.
8. Watanave M, Matsuzaki Y, Nakajima Y, Ozawa A, Yamada M, Hirai H. Contribution of Thyrotropin-Releasing Hormone to Cerebellar Long-Term Depression and Motor Learning. Front Cell Neurosci. 2018 Dec 12;12:490. doi: 10.3389/fncel.2018.00490. Erratum in: Front Cell Neurosci. 2024 Sep 26;18:1495155. doi: 10.3389/fncel.2024.1495155. PMID: 30618637; PMCID: PMC6299015.
9. Mellow AM, Sunderland T, Cohen RM, Lawlor BA, Hill JL, Newhouse PA, Cohen MR, Murphy DL. Acute effects of high-dose thyrotropin-releasing hormone infusions in Alzheimer’s disease. Psychopharmacology (Berl). 1989;98(3):403-7. doi: 10.1007/BF00451695. PMID: 2501817.